Home > Pulmonology > ERS 2019 > COPD Management > One Blood Eosinophil Count Is Sufficient to Guide ICS Therapy

One Blood Eosinophil Count Is Sufficient to Guide ICS Therapy

Presented By
Prof. Mona Bafadhel, University of Oxford, United Kingdom
Conference
ERS 2019
Trial
IMPACT

Blood eosinophil count is a marker for the response of chronic obstructive pulmonary disease (COPD) patients to inhaled corticosteroids (ICS). A post-hoc analysis of the IMPACT trial showed that a single assessment of eosinophils is sufficient to guide treatment decisions for ICS [1].

Recent studies have demonstrated a positive correlation between blood eosinophil count in COPD patients and the magnitude of response to ICS in terms of exacerbation [2]. As Prof. Mona Bafadhel (University of Oxford, United Kingdom) pointed out, current GOLD guidelines recommend using blood eosinophil counts to assist clinicians in predicting the likelihood of beneficial response to ICS [3]. As there is a high intra-individual variation of eosinophils, it is not clear how many eosinophil measurements are sufficient to predict ICS response in COPD.

In their study, Prof. Bafadhel and colleagues used data from the IMPACT trial. In this trial the magnitude of benefit of re...



please login to read the entire article:


You need to register to read the entire article, please do so now.





Posted on